Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,007 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration.
Meredith EL, Mainolfi N, Poor S, Qiu Y, Miranda K, Powers J, Liu D, Ma F, Solovay C, Rao C, Johnson L, Ji N, Artman G, Hardegger L, Hanks S, Shen S, Woolfenden A, Fassbender E, Sivak JM, Zhang Y, Long D, Cepeda R, Liu F, Hosagrahara VP, Lee W, Tarsa P, Anderson K, Elliott J, Jaffee B. Meredith EL, et al. Among authors: elliott j. J Med Chem. 2015 Dec 10;58(23):9273-86. doi: 10.1021/acs.jmedchem.5b01227. Epub 2015 Nov 30. J Med Chem. 2015. PMID: 26568411
The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.
Adams CM, Anderson K, Artman G 3rd, Bizec JC, Cepeda R, Elliott J, Fassbender E, Ghosh M, Hanks S, Hardegger LA, Hosagrahara VP, Jaffee B, Jendza K, Ji N, Johnson L, Lee W, Liu D, Liu F, Long D, Ma F, Mainolfi N, Meredith EL, Miranda K, Peng Y, Poor S, Powers J, Qiu Y, Rao C, Shen S, Sivak JM, Solovay C, Tarsa P, Woolfenden A, Zhang C, Zhang Y. Adams CM, et al. Among authors: elliott j. J Med Chem. 2018 Feb 22;61(4):1622-1635. doi: 10.1021/acs.jmedchem.7b01731. Epub 2018 Feb 5. J Med Chem. 2018. PMID: 29400470
Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach.
Lorthiois E, Roache J, Barnes-Seeman D, Altmann E, Hassiepen U, Turner G, Duvadie R, Hornak V, Karki RG, Schiering N, Weihofen WA, Perruccio F, Calhoun A, Fazal T, Dedic D, Durand C, Dussauge S, Fettis K, Tritsch F, Dentel C, Druet A, Liu D, Kirman L, Lachal J, Namoto K, Bevan D, Mo R, Monnet G, Muller L, Zessis R, Huang X, Lindsley L, Currie T, Chiu YH, Fridrich C, Delgado P, Wang S, Hollis-Symynkywicz M, Berghausen J, Williams E, Liu H, Liang G, Kim H, Hoffmann P, Hein A, Ramage P, D'Arcy A, Harlfinger S, Renatus M, Ruedisser S, Feldman D, Elliott J, Sedrani R, Maibaum J, Adams CM. Lorthiois E, et al. Among authors: elliott j. J Med Chem. 2020 Aug 13;63(15):8088-8113. doi: 10.1021/acs.jmedchem.0c00279. Epub 2020 Jul 21. J Med Chem. 2020. PMID: 32551603
N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.
Elliott JM, Carling RW, Chambers M, Chicchi GG, Hutson PH, Jones AB, MacLeod A, Marwood R, Meneses-Lorente G, Mezzogori E, Murray F, Rigby M, Royo I, Russell MG, Sohal B, Tsao KL, Williams B. Elliott JM, et al. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5748-51. doi: 10.1016/j.bmcl.2006.08.086. Epub 2006 Sep 6. Bioorg Med Chem Lett. 2006. PMID: 16950620
NK1 antagonists based on seven membered lactam scaffolds.
Elliott JM, Carlson EJ, Chicchi GG, Dirat O, Dominguez M, Gerhard U, Jelley R, Jones AB, Kurtz MM, Tsao Kl, Wheeldon A. Elliott JM, et al. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2929-32. doi: 10.1016/j.bmcl.2006.02.080. Epub 2006 Mar 29. Bioorg Med Chem Lett. 2006. PMID: 16574413
N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.
Elliott JM, Carling RW, Chicchi GG, Crawforth J, Hutson PH, Jones AB, Kelly S, Marwood R, Meneses-Lorente G, Mezzogori E, Murray F, Rigby M, Royo I, Russell MG, Shaw D, Sohal B, Tsao KL, Williams B. Elliott JM, et al. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5752-6. doi: 10.1016/j.bmcl.2006.08.085. Epub 2006 Sep 6. Bioorg Med Chem Lett. 2006. PMID: 16950617
2-Aryl indole NK(1) antagonists: optimisation of the amide substituent.
Shaw D, Chicchi GG, Elliott JM, Kurtz M, Morrison D, Ridgill MP, Szeto N, Watt AP, Williams AR, Swain CJ. Shaw D, et al. Among authors: elliott jm. Bioorg Med Chem Lett. 2001 Dec 3;11(23):3031-4. doi: 10.1016/s0960-894x(01)00616-3. Bioorg Med Chem Lett. 2001. PMID: 11714604
Aryl sulfones: a new class of gamma-secretase inhibitors.
Teall M, Oakley P, Harrison T, Shaw D, Kay E, Elliott J, Gerhard U, Castro JL, Shearman M, Ball RG, Tsou NN. Teall M, et al. Among authors: elliott j. Bioorg Med Chem Lett. 2005 May 16;15(10):2685-8. doi: 10.1016/j.bmcl.2004.12.017. Bioorg Med Chem Lett. 2005. PMID: 15863342
4,007 results